CELYAD ONCOLOGY earnings
Annual earnings per share (EUR per share, as reported)
| Fiscal year | Period end | Diluted EPS | Basic EPS | Filed |
|---|---|---|---|---|
| 2024 | 2024-12-31 | €-0.14 | €-0.14 | 2026-06-19T06:18:14Z |
| 2023 | 2023-12-31 | €-0.34 | €-0.34 | 2026-06-19T06:18:14Z |
Revenue & profit (EUR)
| Concept | 2024 | 2023 |
|---|---|---|
| Revenue | €186.0K | €102.0K |
| Profit for the year | -€5.8M | -€8.4M |
Methodology
Earnings per share comes from ifrs-full:DilutedEarningsLossPerShare /
ifrs-full:BasicEarningsLossPerShare; revenue from
ifrs-full:Revenue and profit from ifrs-full:ProfitLoss,
as tagged in CELYAD ONCOLOGY's ESEF annual reports (source:
filings.xbrl.org).
Figures are in EUR, as reported. Not investment advice.